Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
Trial details
- Registry ID
- NCT05217667
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)NCT05217667 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2023-05-02Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |